Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Celator Pharmaceuticals and Cephalon have decided to expand their existing research agreement into the next stage of development.
Subscribe to our email newsletter
Under the agreement, Cephalon will use Celator’s proprietary technology in an ongoing drug development and life-cycle management program at Cephalon.
Celator Pharma CEO Scott Jackson said they are pleased that they progress to date allows Cephalon and Celator to advance this promising work.
"It is rewarding to have a company of Cephalon’s stature demonstrate the potential of our technology in its portfolio and make the ongoing financial commitment to continue this research," Jackson said.